HomeInsightsStock Comparison

Bharat Parenterals Ltd vs Wockhardt Ltd Stock Comparison

Bharat Parenterals Ltd vs Wockhardt Ltd Stock Comparison

Last Updated on: Apr 25, 2025

Key Highlights

  • The Latest Trading Price of Bharat Parenterals Ltd is ₹ 940 as of 25 Apr 15:30.
  • The P/E Ratio of Bharat Parenterals Ltd changed from 3.4 on March 2020 to 45 on March 2024 . This represents a CAGR of 67.63% over 5 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.6 on March 2021 to 0 on March 2024 . This represents a CAGR of -100.00% over 4 years.
  • The Market Cap of Bharat Parenterals Ltd changed from ₹ 81.25 crore on March 2020 to ₹ 648.03 crore on March 2024 . This represents a CAGR of 51.48% over 5 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 1912 crore on March 2020 to ₹ 8951 crore on March 2024 . This represents a CAGR of 36.16% over 5 years.
  • The revenue of Bharat Parenterals Ltd for the Dec '24 is ₹ 75.2 crore as compare to the Sep '24 revenue of ₹ 75.84 crore. This represent the decline of -0.84% The revenue of Wockhardt Ltd for the Dec '24 is ₹ 729 crore as compare to the Sep '24 revenue of ₹ 818 crore. This represent the decline of -10.88%.
  • The ebitda of Bharat Parenterals Ltd for the Dec '24 is ₹ 6.59 crore as compare to the Sep '24 ebitda of ₹ -3.45 crore. This represent the decline of -291% The ebitda of Wockhardt Ltd for the Dec '24 is ₹ 136 crore as compare to the Sep '24 ebitda of ₹ 119 crore. This represent the growth of 14.29%.
  • The net profit of Bharat Parenterals Ltd changed from ₹ 7.01 crore to ₹ -7.87 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Wockhardt Ltd changed from ₹ -136 crore to ₹ 20 crore over 7 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.58 % on March 2024 . This represents a CAGR of 20.39% over 2 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bharat Parenterals Ltd

  • Bharat Parenterals Ltd. was incorporated on Sep.'92 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
  • The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
  • It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company effective 09 July, 2016.
  • Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
  • Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective 28th June, 2022.

About Wockhardt Ltd

  • Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
  • The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
  • It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
  • It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
  • Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

Bharat Parenterals Ltd News Hub

News

Bharat Parenterals to announce Quarterly Result

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 3 Febru...

Read more

24 Jan 2025 10:28

News

Bharat Parenterals to announce Quarterly Result

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 29 Octo...

Read more

21 Oct 2024 10:22

News

Bharat Parenterals announces board meeting date

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 8 Augus...

Read more

01 Aug 2024 10:54

News

Bharat Parenterals schedules AGM

Bharat Parenterals announced that the Annual General Meeting (AGM) of the company will be ...

Read more

12 Jun 2024 10:01

News

Bharat Parenterals to hold board meeting

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 10 June...

Read more

07 Jun 2024 10:29

News

Bharat Parenterals schedules board meeting

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 5 June ...

Read more

27 May 2024 17:42

Wockhardt Ltd News Hub

News

Wockhardt announces incorporation of step-down subsidiary in Ireland

Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiar...

Read more

08 Apr 2025 19:55

News

Wockhardt surges after breakthrough US cancer treatment with Zaynich

The 15-year-old patient, diagnosed with Acute Myeloid Leukemia (AML), had been battling a ...

Read more

01 Apr 2025 11:32

News

Wockhardt announces board meeting date

Wockhardt will hold a meeting of the Board of Directors of the Company on 7 February 2025....

Read more

03 Feb 2025 16:52

News

Wockhardt spurts after Indian drug regulator approves Pneumonia antibiotic

Miqnaf is an ultra-short course, once-a-day, 3-day treatment for CABP, including those cau...

Read more

03 Jan 2025 11:22

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 13 November 2024...

Read more

08 Nov 2024 16:42

News

Wockhardt slumps on launching QIP at discount

The floor price indicates a steep discount of 8.5% over the stock's closing price on Wedne...

Read more

07 Nov 2024 14:38

SWOT Analysis Of Wockhardt Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Bharat Parenterals Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Wockhardt Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Bharat Parenterals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bharat Parenterals Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Bharat Parenterals Ltd or Wockhardt Ltd?

Market cap of Bharat Parenterals Ltd is 647 Cr while Market cap of Wockhardt Ltd is 22,688 Cr

What are the key factors driving the stock performance of Bharat Parenterals Ltd and Wockhardt Ltd?

The stock performance of Bharat Parenterals Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Parenterals Ltd and Wockhardt Ltd?

As of April 25, 2025, the Bharat Parenterals Ltd stock price is INR ₹940.0. On the other hand, Wockhardt Ltd stock price is INR ₹1396.35.

How do dividend payouts of Bharat Parenterals Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Bharat Parenterals Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions